Gilberto Lopes, MD
Medical Oncology · Miami, FLNPI 1912350596
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Astrazeneca UK Limited at 25.6% of the total. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $1599.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$25K
- Merck$19K
- AstraZeneca$14K
- Dr.reddy's Laboratories,inc.$10K
- Mirati Therapeutics, Inc.$7K
- Rigel Pharmaceuticals, Inc.$6K
- plus $18K from 12 others
Across 240 payments — averaging $9592.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$481K
- Blueprint Medicines Corporation$449K
- GSK$287K
- EMD Serono, Inc.$255K
- Beone Medicines USA, Inc.$153K
- Pfizer$148K
- plus $530K from 10 others
What the payments were for
- Consulting fees$51,03951%
- Speaking & faculty fees$38,81039%
- Travel & lodging$7,8558%
- Food & beverage$1,4521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 2 | $25,345 |
| Merck | 6 | $19,447 |
| AstraZeneca | 16 | $14,138 |
| Dr.reddy's Laboratories,inc. | 4 | $9,750 |
| Mirati Therapeutics, Inc. | 3 | $6,623 |
| Rigel Pharmaceuticals, Inc. | 6 | $5,887 |
| Blueprint Medicines Corporation | 2 | $5,320 |
| Coherus Oncology, Inc. | 6 | $4,238 |
| Beone Medicines USA, Inc. | 2 | $3,750 |
| Janssen Global Services, LLC | 3 | $2,363 |
| Regeneron | 1 | $1,654 |
| Johnson & Johnson | 2 | $204 |
| Beigene USA, Inc. | 1 | $130 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $98 |
| Seagen Inc. | 3 | $43 |
| Pfizer | 2 | $31 |
| Bristol Myers Squibb | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$99,157 in reported general payments places this provider in the 90th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlecensaAlectinib Hcl | 27 | $486,830 |
| TagrissoOsimertinib Mesylate | 25 | $448,958 |
| BraftoviEncorafenib | 13 | $207,846 |
| MektoviBinimetinib | 13 | $203,925 |
| EliquisApixaban | 30 | $17,177 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,218 |
| Doxycycline Hyclate | 31 | $1,208 |
| Celecoxib | 15 | $1,201 |
| Oxycodone Hcl | 18 | $685 |
| Hydrocortisone | 15 | $389 |
| Dexamethasone | 15 | $354 |
| Olanzapine | 14 | $315 |
| Ondansetron OdtOndansetron | 27 | $258 |
| Omeprazole | 20 | $245 |
| ClopidogrelClopidogrel Bisulfate | 12 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $14,138 | $448,95825 claims |
| PfizerEliquis | $31 | $17,17730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Miami
- Neil LoveMiami$5.6M
- Sarbajit MukherjeeMiami$232K
- Bruna Pellini FerreiraMiami$158K
- Coral OlazagastiMiami$134K
- Jonathan TrentMiami$102K
- Craig MoskowitzMiami$94K
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.